238749-53-6

Basic information

• Product Name: ethyl 4H-pyrrolo[2,3-d][1,3]thiazole-5-carboxylate
• Synonyms: ethyl 4H-pyrrolo[2,3-d][1,3]thiazole-5-carboxylate
• CAS NO: 238749-53-6
• Molecular Formula: C8H8N2O2S
• Molecular Weight: 196.22632
• Mol File: 238749-53-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 352.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.411±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.53±0.30(Predicted)
• CAS DataBase Reference: ethyl 4H-pyrrolo[2,3-d][1,3]thiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4H-pyrrolo[2,3-d][1,3]thiazole-5-carboxylate(238749-53-6)
• EPA Substance Registry System: ethyl 4H-pyrrolo[2,3-d][1,3]thiazole-5-carboxylate(238749-53-6)

Safety Data

• Hazardous Substances Data: 238749-53-6(Hazardous Substances Data)

Upstream product

• 1003-32-3 thiazole-5-carboxaldehyde 
• 1007389-04-9 ethyl 2-azido-3-(thiazol-5-yl)acrylate 

Relevant articles and documents

Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus

Chikungunya virus (CHIKV) is a re-emerging vector-borne alphavirus, and there is no approved effective antiviral treatment currently available for CHIKV. We previously reported the discovery of thieno[3,2-b]pyrrole 1b that displayed good antiviral activit

The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I

The present invention discloses and claims compounds of formula (I) and formula (II), as inhibitors of human casein kinase Iε and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and slee